Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

American Thoracic Society

May 17-22, 2019 Dallas,  Texas – USA Booth #3619

EB 2019

April 6-9, 2019 Orlando, Florida - USA Booth #916

Japanese Respiratory Society Annual Meeting

April 12-14, 2019 Tokyo – JAPAN Booth#46

Japanese Pharmacological Society

March 14-16, 2019 Osaka - JAPAN